Stocktoria
Takeda Pharmaceutical Company Limited 4502.T
JP · Tokyo Stock Exchange · XTKS · stock · Healthcare · website
Takeda Pharmaceutical Company Limited financials (annual, from 10-K)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $4.51T | $4.58T | $4.26T | $4.03T |
| Gross profit | $2.93T | $3.00T | $2.84T | $2.78T |
| R&D expense | $675.9B | $730.2B | $729.9B | $633.3B |
| SG&A expense | $1.08T | $1.10T | $1.05T | $997.3B |
| Operating income | $464.5B | $466.4B | $309.9B | $587.8B |
| Interest expense | $148.1B | $137.3B | $119.5B | $117.0B |
| Income tax | $9.8B | $66.9B | -$91.4B | $58.1B |
| Net income | -$152.4B | $107.9B | $144.1B | $317.0B |
| EPS (diluted) | $-96.75 | $67.23 | $91.16 | $201.94 |
| Operating cash flow | $1.04T | $1.06T | $716.3B | $977.2B |
| Free cash flow | $626.8B | $677.6B | $235.6B | $343.5B |
| Cash & equivalents | $595.1B | $385.1B | $457.8B | $533.5B |
| Inventory | $1.40T | $1.22T | $1.21T | $986.5B |
| Total assets | $15.51T | $14.25T | $15.11T | $13.96T |
| Total liabilities | $8.08T | $7.31T | $7.83T | $7.60T |
| Shareholders' equity | $7.43T | $6.94T | $7.27T | $6.35T |
Growth · year-over-year · Revenue CAGR 3.8%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | -1.7% | +7.5% | +5.9% | — |
| Net income growth | -241.2% | -25.1% | -54.6% | — |
| EPS growth | -243.9% | -26.3% | -54.9% | — |
| Free cash flow growth | -7.5% | +187.6% | -31.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · JP · as of 2026-03-31. Figures in JPY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.